title: Inhibition of protein synthesis by aminoglycoside-arginine conjugates.
abstract: Inhibition of translation by small molecule ligands has proven to be a useful tool for understanding this complex cellular mechanism, as well as providing drugs of significant medical importance. Many small molecule ligands inhibit translation by binding to RNA or RNA/protein components of the ribosomal subunits and usurping their function. A class of peptidomimetics [aminoglycoside-arginine conjugates (AAC)] has recently been designed to inhibit HIV TAR/tat interaction and in experiments aimed at assessing the inhibitory effects of AACs on TAR-containing transcripts, we found that AACs are general inhibitors of translation. Experiments reported herein aim at characterizing these novel properties of AACs. We find that AACs are inhibitors of eukaryotic and prokaryotic translation and exert their effects by blocking peptide chain elongation. Structure/activity relationship studies suggest that inhibition of translation by AACs is directly related to the number of arginine groups present on the aminoglycoside backbone and to the nature of the core aminoglycoside. AACs are therefore attractive tools for understanding and probing ribosome function.
authors.affiliation: Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
authors.forename: Marjolaine
authors.initials: M
authors.lastname: Carriere
authors.forename: Veerappan
authors.initials: V
authors.lastname: Vijayabaskar
authors.forename: Drew
authors.initials: D
authors.lastname: Applefield
authors.forename: Isabelle
authors.initials: I
authors.lastname: Harvey
authors.forename: Philippe
authors.initials: P
authors.lastname: Garneau
authors.forename: Jon
authors.initials: J
authors.lastname: Lorsch
authors.forename: Aviva
authors.initials: A
authors.lastname: Lapidot
authors.forename: Jerry
authors.initials: J
authors.lastname: Pelletier
mesh_terms: D000617:Aminoglycosides / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D001120:Arginine / Q000737:chemistry / Q000494:pharmacology; D005057:Eukaryotic Cells / Q000502:physiology; D005260:Female; D005601:Framycetin / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology; D016325:HIV Long Terminal Repeat / Q000235:genetics; D020128:Inhibitory Concentration 50; D009865:Oocytes / Q000502:physiology; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology; D014176:Protein Biosynthesis / Q000187:drug effects; D011500:Protein Synthesis Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D014982:Xenopus laevis
chemical_list: D000617:Aminoglycosides; D010455:Peptides; D011500:Protein Synthesis Inhibitors; C444521:neomycin B-arginine conjugate NeoR; D005601:Framycetin; D001120:Arginine